GPCR Biology-Informed Drug Discovery in Asthma.
Publication/Presentation Date
8-14-2026
Abstract
Advances in GPCR biology and drug-discovery technology are simultaneously reshaping what can be targeted in asthma and how those strategies must be validated. Recent insights into biased signaling, receptor dimerization and signaling microdomains have revealed new therapeutic opportunities beyond the limitations of traditional β₂-agonist bronchodilation and cytokine-targeted biologics. At the same time, innovations in structural biology, computational modeling, machine learning, biosensor-based pharmacology, and physiologically relevant airway models have transformed the interrogation of GPCRs and the engineering of therapeutics that target them. This review synthesizes these developments, emphasizing how emerging GPCR concepts inform modern discovery platforms, how receptor- and post-receptor signaling control points can be targeted, and how validation across artificial and physiologic systems improves translational fidelity. We further discuss how GPCR therapeutics may reshape clinical development and complement existing biologic therapies in asthma.
ISSN
1535-4989
Published In/Presented At
Penn R. B. (2026). GPCR Biology-Informed Drug Discovery in Asthma. American journal of respiratory cell and molecular biology, aanag168. Advance online publication. https://doi.org/10.1093/ajrcmb/aanag168
Disciplines
Business Administration, Management, and Operations | Health and Medical Administration | Management Sciences and Quantitative Methods
PubMedID
42596590
Department(s)
Administration and Leadership
Document Type
Article